Document Type
Article
Publication Date
11-1-2014
Abstract
One of the key mechanisms by which prostate cancer cells evade hormone therapy is through intratumor testosterone production. New evidence points toward androstenedione as a potential precursor of intratumor androgen production and furthers nomination of AKR1C3 as a therapeutic target in advanced disease. Clin Cancer Res; 20(21); 5343-5. ©2014 AACR.
Recommended Citation
Knudsen, Karen E, "Hormone whodunit: clues for solving the case of intratumor androgen production." (2014). Department of Cancer Biology Faculty Papers. Paper 69.
https://jdc.jefferson.edu/cbfp/69
PubMed ID
25135482
Comments
This article has been peer reviewed. It is the author’s final published version in Clinical Cancer Research Volume 20, Issue 21, November 2014, Pages 5343-5345.
The published version is available at DOI: 10.1158/1078-0432.CCR-14-1188. Copyright © American Association for Cancer Research